Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1998 1
2002 1
2006 2
2011 8
2012 5
2013 8
2014 7
2015 8
2016 7
2017 9
2018 15
2019 10
2020 17
2021 13
2022 11
2023 27
2024 22
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Angiogenesis Assays.
Nambiar DK, Kujur PK, Singh RP. Nambiar DK, et al. Methods Mol Biol. 2016;1379:107-15. doi: 10.1007/978-1-4939-3191-0_10. Methods Mol Biol. 2016. PMID: 26608294
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.
Beach C, MacLean D, Majorova D, Melemenidis S, Nambiar DK, Kim RK, Valbuena GN, Guglietta S, Krieg C, Darvish-Damavandi M, Suwa T, Easton A, Hillson LV, McCulloch AK, McMahon RK, Pennel K, Edwards J, O'Cathail SM, Roxburgh CS, Domingo E, Moon EJ, Jiang D, Jiang Y, Zhang Q, Koong AC, Woodruff TM, Graves EE, Maughan T, Buczacki SJ, Stucki M, Le QT, Leedham SJ, Giaccia AJ, Olcina MM. Beach C, et al. Among authors: nambiar dk. J Clin Invest. 2023 Dec 1;133(23):e168277. doi: 10.1172/JCI168277. J Clin Invest. 2023. PMID: 37824211 Free PMC article.
Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.
Beach C, MacLean D, Majorova D, Melemenidis S, Nambiar DK, Kim RK, Valbuena GN, Guglietta S, Krieg C, Darvish-Damavandi M, Suwa T, Easton A, Hillson LV, McCulloch AK, McMahon RK, Pennel K, Edwards J, O'Cathail SM, Roxburgh CS, Domingo E, Moon EJ, Jiang D, Jiang Y, Zhang Q, Koong AC, Woodruff TM, Graves EE, Maughan T, Buczacki SJ, Stucki M, Le QT, Leedham SJ, Giaccia AJ, Olcina MM. Beach C, et al. Among authors: nambiar dk. J Clin Invest. 2024 Aug 15;134(16):e185067. doi: 10.1172/JCI185067. J Clin Invest. 2024. PMID: 39145459 Free PMC article. No abstract available.
NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells.
Guan L, Nambiar DK, Cao H, Viswanathan V, Kwok S, Hui AB, Hou Y, Hildebrand R, von Eyben R, Holmes BJ, Zhao J, Kong CS, Wamsley N, Zhang W, Major MB, Seol SW, Sunwoo JB, Hayes DN, Diehn M, Le QT. Guan L, et al. Among authors: nambiar dk. Cancer Res. 2023 Mar 15;83(6):861-874. doi: 10.1158/0008-5472.CAN-22-1903. Cancer Res. 2023. PMID: 36652552 Free PMC article.
Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate Cancer.
Lee W, Chung JY, Baidoo KE, Nambiar D, Basuli F, Coleman I, Bakht M, Li C, Shin J, Jeong SU, Cho YM, Beltran H, Nelson PS, Sowalsky AG, Choyke PL, Escorcia FE. Lee W, et al. Among authors: nambiar d. Eur Urol. 2025 Sep;88(3):301-303. doi: 10.1016/j.eururo.2025.05.007. Epub 2025 May 21. Eur Urol. 2025. PMID: 40404528 No abstract available.
180 results